Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Portfolio Pulse from Vandana Singh
Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, has attracted attention from analysts at Guggenheim Partners and Cantor Fitzgerald. Both firms initiated coverage with positive ratings, citing the potential of Alumis' lead asset ESK-001 and its brain-penetrant TYK2 inhibitor A-005. Guggenheim set a price target of $32, while Cantor highlighted the company's modest valuation and commercial potential. Alumis recently raised $250 million through its IPO and private placement.
July 24, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alumis Inc. has received positive analyst coverage from Guggenheim Partners and Cantor Fitzgerald, highlighting the potential of its lead asset ESK-001 and brain-penetrant TYK2 inhibitor A-005. Guggenheim set a price target of $32, and Cantor emphasized the company's modest valuation and commercial potential.
The positive analyst coverage and high price target from Guggenheim, along with Cantor's emphasis on the company's commercial potential and modest valuation, are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Bristol-Myers Squibb's BMS-322 is mentioned as a direct competitor to Alumis' ESK-001 in the development of oral therapies for immune-mediated diseases.
While BMS-322 is mentioned as a competitor, the primary focus of the article is on Alumis. The impact on Bristol-Myers Squibb's stock is likely to be neutral in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 30
NEUTRAL IMPACT
Johnson & Johnson's JNJ-2113 is mentioned as a direct competitor to Alumis' ESK-001 in the development of oral therapies for immune-mediated diseases.
While JNJ-2113 is mentioned as a competitor, the primary focus of the article is on Alumis. The impact on Johnson & Johnson's stock is likely to be neutral in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 30
NEUTRAL IMPACT
Takeda Pharmaceutical's TAK-279 is mentioned as a direct competitor to Alumis' ESK-001 in the development of oral therapies for immune-mediated diseases.
While TAK-279 is mentioned as a competitor, the primary focus of the article is on Alumis. The impact on Takeda Pharmaceutical's stock is likely to be neutral in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 30